ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with
ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian
tube or primary peritoneal carcinoma.